As above discussed, small cell neuroendocrine cancer is a very aggressive subset of prostate cancer that is rare at time of diagnosis but increasingly more frequent following emergence of resistance to AR-targeted therapies and thus represents one of the mechanisms of AR-resistance in CRPCs. The gene discussed is AR; the disease is prostate cancer.